---
title: Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
nct_id: NCT05064735
overall_status: COMPLETED
phase: PHASE3
sponsor: Novo Nordisk A/S
study_type: INTERVENTIONAL
primary_condition: Obesity
countries: United States, Canada, Colombia, Denmark, France, Norway, Russia, Saudi Arabia, South Africa, Spain, Sweden
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05064735.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05064735"
ct_last_update_post_date: 2025-11-17
last_seen_at: "2026-05-12T06:00:22.304Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

**Official Title:** Effect of Subcutaneous Semaglutide 2.4 mg Once-weekly Compared to Placebo in Subjects With Obesity and Knee Osteoarthritis

**NCT ID:** [NCT05064735](https://clinicaltrials.gov/study/NCT05064735)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 407
- **Lead Sponsor:** Novo Nordisk A/S
- **Conditions:** Obesity
- **Start Date:** 2021-10-01
- **Completion Date:** 2023-09-08
- **CT.gov Last Update:** 2025-11-17

## Brief Summary

This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pain in the knee in people taking semaglutide with people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance.

Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. During the study, participants will have talks with study staff about how to eat healthy food and how to be more physically active. The study will last for about 1 ½ years. Participants will have 14 clinic visits with the study staff. At the first clinic visit participants will have a blood sample taken. Participants will have an X-ray of participants knee taken at the first visit. If participants have had an X-ray recently, this may not be needed.

At 6 of the clinic visits participants cannot take pain medications for 3 days before the visit. Participants cannot take part if participants have had a joint replacement surgery in participants knee. Participants cannot take part if participants have or have had diabetes. Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Male or female, age above or equal to 18 years at the time of signing informed consent
* Body Mass Index (BMI) equal to or greater than 30.0 kg/m\^2
* Clinical diagnosis of knee OA (American College of Rheumatology (ACR) criteria) with moderate radiographic changes (Kellgren-Lawrence (KL) grades 2 or 3 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees are equal target knee joint will be in the most dominant leg.
* Pain due to knee OA

Exclusion Criteria:

* Joint replacement in target knee
* Arthroscopy or injections into target knee within last 3 months prior to enrolment
* Any other joint disease in the target knee
```

## Arms

- **semaglutide 2.4 mg** (EXPERIMENTAL) — Participants will receive semaglutide subcutaneous (s.c) 2.4 mg once-weekly as adjunct to a reduced-calorie diet and increased physical activity
- **semaglutide 2.4 mg (placebo)** (PLACEBO_COMPARATOR) — Participants will receive semaglutide subcutaneous (s.c) placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity

## Interventions

- **semaglutide 2.4 mg** (DRUG) — semaglutide subcutaneous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
- **semaglutide 2.4 mg (placebo)** (DRUG) — semaglutide subcutanous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity

## Primary Outcomes

- **Percentage Change in Body Weight** _(time frame: Baseline (week 0), end of treatment (week 68))_ — Percentage change in body weight from baseline (week 0) to end of treatment (week 68) is presented. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.
- **Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score** _(time frame: Baseline (week 0), end of treatment (week 68))_ — WOMAC is a disease-specific patient-reported outcome measure designed to assess changes in symptoms and lower extremity functioning associated with treatment in patients with osteoarthritis of the hip and/or knee. WOMAC is a 24 item questionnaire which assesses clinically important, participant-relevant symptoms in area of pain, stiffness, and physical function in participants with osteoarthritis (OA). It consists of 3 subscales: pain, stiffness and physical function. The WOMAC raw pain score is derived as the sum of the 5 item scores in the pain domain. It will be normalised and expressed on a 0-100 scale. This is done by dividing raw score by the highest possible value of the raw score for the pain domain (i.e. 50) and multiplying by 100. Higher scores indicate worse outcome. The outcome measure was evaluated based on the data from in-trial period. In-trial period was defined as the uninterrupted time interval from date of randomization to date of last contact with trial site.

## Secondary Outcomes

- **Percentage of Participants Achieving Body Weight Reduction Greater Than or Equal to (≥) 5 Percent (%) (Yes/No)** _(time frame: From baseline (week 0) to end of treatment (week 68))_
- **Percentage of Participants Achieving Body Weight Reduction ≥ 10% (Yes/No)** _(time frame: From baseline (week 0) to end of treatment (week 68))_
- **Change in WOMAC Physical Function Score** _(time frame: Baseline (week 0), end of treatment (week 68))_
- **Change in Short Form 36 (SF-36) Physical Functioning Score** _(time frame: Baseline (week 0), end of treatment (week 68))_
- **Change in Waist Circumference** _(time frame: Baseline (week 0), end of treatment (week 68))_
- **Change in WOMAC Stiffness Score** _(time frame: Baseline (week 0), end of treatment (week 68))_
- **Change in WOMAC Total Score** _(time frame: Baseline (week 0), end of treatment (week 68))_
- **Change in SF-36 Bodily Pain Score** _(time frame: Baseline (week 0), end of treatment (week 68))_
- **Change in SF-36 Physical Component Summary** _(time frame: Baseline (week 0), end of treatment (week 68))_
- **Change in SF-36 Mental Component Summary** _(time frame: Baseline (week 0), end of treatment (week 68))_
- **Percentage of Participants Using Allowed Rescue Analgesics During Wash Out (Yes/No)** _(time frame: At end of treatment (week 68))_
- **Amount of Allowed Rescue Analgesics Used During Wash Out** _(time frame: At end of treatment (week 68))_
- **Percentage of Participants With Use of Pain Medication** _(time frame: From baseline (week 0) to end of treatment (week 68))_
- **Change in Pain Intensity (Numerical Rating Scale [NRS])** _(time frame: Baseline (week 0), end of treatment (week 68))_
- **Percentage of Participants Achieving Body Weight Reduction ≥ 15% (Yes/No)** _(time frame: From baseline (week 0) to end of treatment (week 68))_
- **Percentage of Participants Achieving Body Weight Reduction ≥ 20% (Yes/No)** _(time frame: From baseline (week 0) to end of treatment (week 68))_
- **Percentage of Participants Achieving WOMAC Pain Reduction ≥ 30% (Yes/No)** _(time frame: From baseline (week 0) to end of treatment (week 68))_
- **Percentage of Participants Achieving WOMAC Pain Reduction ≥ 50% (Yes/No)** _(time frame: From baseline (week 0) to end of treatment (week 68))_
- **Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participant Change in WOMAC Pain Score (Yes/No)** _(time frame: From baseline (week 0) to end of treatment (week 68))_
- **Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participant Change in WOMAC Physical Function Score (Yes/No)** _(time frame: From baseline (week 0) to end of treatment (week 68))_
- **Percentage of Participants Achieving Threshold for Clinically Meaningful Within-participant Change in SF-36 Physical Functioning Score (Yes/No)** _(time frame: From baseline (week 0) to end of treatment (week 68))_
- **Percentage of Participants Achieving Pain Intensity (Numerical Rating Scale [NRS]) Reduction ≥ 30% (Yes/No)** _(time frame: From baseline (week 0) to end of treatment (week 68))_
- **Percentage of Participants Achieving Pain Intensity (Numerical Rating Scale [NRS]) Reduction ≥ 50% (Yes/No)** _(time frame: From baseline (week 0) to end of treatment (week 68))_

## Locations (122)

- Baptist Health System, Montgomery, Alabama, United States
- Ortho Arizona, Phoenix, Arizona, United States
- Anaheim Clinical Trials, LLC, Anaheim, California, United States
- Stuart L. Silverman MD - A Medical Corporation, Beverly Hills, California, United States
- Valley Research, Fresno, California, United States
- Providence Medical Foundation, Fullerton, California, United States
- Desert Oasis Hlthcr Med Group, Palm Springs, California, United States
- Encompass Clinical Research_Spring Valley, Spring Valley, California, United States
- Diablo Clinical Research, Inc., Walnut Creek, California, United States
- Clinical Research of Hollywood_Hollywood, Hollywood, Florida, United States
- Westside Center For Clinical Research, Jacksonville, Florida, United States
- Jacksonville Ctr For Clin Res, Jacksonville, Florida, United States
- Well Pharma Medical Research Corp, Miami, Florida, United States
- Renstar Medical Research, Ocala, Florida, United States
- Clinical Trial Res Assoc,Inc, Plantation, Florida, United States
- East West Medical Research Institute_Honolulu, Honolulu, Hawaii, United States
- Clinical Invest Special_Gurnee, Gurnee, Illinois, United States
- Evanston Premier Hlthcr Res, Skokie, Illinois, United States
- Clinical Invest Special_Gurnee, Wauconda, Illinois, United States
- MediSphere Medical RC, Evansville, Indiana, United States
- Velocity Clin. Res Valparaiso, Valparaiso, Indiana, United States
- KU MedWest, Shawnee Mission, Kansas, United States
- L-MARC Research Center, Louisville, Kentucky, United States
- Maryland Veterans Administration Health Care System, Baltimore, Maryland, United States
- Centennial Medical Group, Elkridge, Maryland, United States
- Brigham & Women's Hospital, Boston, Massachusetts, United States
- Arcturus Healthcare, PLC., Troy, Michigan, United States
- StudyMetrix Research LLC, City of Saint Peters, Missouri, United States
- The Center For Pharmaceutical Research PC, Kansas City, Missouri, United States
- Sundance Clinical Research LLC, St Louis, Missouri, United States
- NYU Langone Medical Cent-Joan H Tisch Cnt for Women's Health, New York, New York, United States
- Hospital For Special Surgery, New York, New York, United States
- Rochester Clinical Research, Inc., Rochester, New York, United States
- DaVita Clinical Research - New York, The Bronx, New York, United States
- Southgate Medical Group, LLP, West Seneca, New York, United States
- Great Lakes Medical Research, Westfield, New York, United States
- University of North Carolina- Chapel Hill Adults, Chapel Hill, North Carolina, United States
- Medication Mgmnt, LLC_Grnsboro, Greensboro, North Carolina, United States
- PharmQuest Life Sciences LLC, Greensboro, North Carolina, United States
- Raleigh Medical Group, Raleigh, North Carolina, United States
- Accellacare, Wilmington, North Carolina, United States
- Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States
- Velocity Clin Res_Cincinnati, Cincinnati, Ohio, United States
- Louis Stokes Clvlnd VA Med Ctr, Cleveland, Ohio, United States
- Cleveland Clinic_Cleveland, Cleveland, Ohio, United States
- Prestige Clinical Research, Franklin, Ohio, United States
- New Venture Medical Research, Wadsworth, Ohio, United States
- Altoona Osteoporosis Center, Duncansville, Pennsylvania, United States
- The University of Penn Center, Philadelphia, Pennsylvania, United States
- Parkside Family Medicine, Philadelphia, Pennsylvania, United States
- Rhode Island Hospital, Providence, Rhode Island, United States
- Accellacare US Inc._SC, Mt. Pleasant, South Carolina, United States
- Coastal Carolina Res Ctr., North Charleston, South Carolina, United States
- Palmetto Clinical Research, Summerville, South Carolina, United States
- Tennova HC Turkey Creek MC, Knoxville, Tennessee, United States
- PrimeCare Medical Group, Houston, Texas, United States
- Southwest Houston Research Ltd, Houston, Texas, United States
- DM Clin Rsrch/Fam Diag Clinic, Tomball, Texas, United States
- Health Res of Hampton Roads, Newport News, Virginia, United States
- National Clin Res Inc., Richmond, Virginia, United States
- Capital Clin Res Ctr,LLC, Olympia, Washington, United States
- C-endo Diab Endo Clin Calgery, Calgary, Alberta, Canada
- C-endo Diab & Endo Clinic, Edmonton, Alberta, Canada
- Ocean West Research Clinic, Surrey, British Columbia, Canada
- G.A. Research Associates Ltd., Moncton, New Brunswick, Canada
- Commonwealth Medical Clinic, Mount Pearl, Newfoundland and Labrador, Canada
- Manna Research Inc. (Burlington N), Burlington, Ontario, Canada
- Wharton Med Clin Trials, Hamilton, Ontario, Canada
- Premier Clinical Trial Research Network (PCTRN), Hamilton, Ontario, Canada
- Milestone Research, London, Ontario, Canada
- Dr Anil K Gupta Med Prof Corp, Toronto, Ontario, Canada
- Manna Research Inc._Toronto, Toronto, Ontario, Canada
- Centre Medical Acadie, Montreal, Quebec, Canada
- CHU de Quebec-Universite Laval, Québec, Quebec, Canada
- Ctr Méd. et pro d l'Ost d port, Saint-Marc-des-Carrieres, Quebec, Canada
- Institut universitaire de cardiologie, Québec, Canada
- Master Centre for Canada, Toronto, Canada
- Centro de investigación médico asistencial S.A.S, Barranquilla, Colombia
- BLUECARE SALUD S.A.S. Sede Centro Médico Integral, Bogotá, Colombia
- CentrodeInvestigaciónenReumatologíayEspecialidadesMédicas, Bogotá, Colombia
- Preventive Care S.A.S, Chía, Colombia
- Klinik for Led og bindevævssygdomme, Aarhus N, Denmark
- Frederiksberg Hospital - Parker Institutet (Artrose), Frederiksberg, Denmark
- Centre Hospitalier de Clermont-Ferrand-Hopital Gabriel Montpied, Clermont-Ferrand, France
- Groupe Sos Sante-Hopital Le Creusot-Hotel Dieu-2, Le Creusot, France
- Aphp-Hopital La Pitie Salpetriere-3, Paris, France
- CHU Pitié-Salpétrière, Paris, France
- Ap-Hp-Hopital Europeen Georges Pompidou, Paris, France
- Hôpital Européen Georges Pompidou, Paris, France
- Hospices Civils de Lyon-Hopital Lyon Sud-1, Pierre-Bénite, France
- Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-2, Toulouse, France
- Centre de Recherche Clinique Portes Du Sud, Vénissieux, France
- Akershus Universitetssykehus, Nordbyhagen, Norway
- Oslo us HF, Aker sykehus, Oslo, Norway
- Senter for sykelig overvekt i Helse Sør-Øst, Tønsberg, Norway
- PIH "Clin Hosp "RZD-Medicina" former Kazan OJSC Rus Railways, Kazan', Russia
- LLC Medical center "Maksimum Zdorovia", Kemerovo, Russia
- FSBI 'I.I. Dedov National Medical Research Center of Endocrinology' of the MH of Russia, Moscow, Russia
- Setchenov First Moscow State Medical University, Moscow, Russia
- Federal Bureau for Medical and Social Expertise, Moscow, Russia
- Consultative & Diagnostic Center with a Outpatient Hospital, Saint Petersburg, Russia
- SIH "Saratov Regional Clinical Hospital for War Veterans", Saratov, Russia
- Siberian State Medical University, Tomsk, Russia
- Voronezh Regional Clinical Consultive-diagnostic Centre, Voronezh, Russia
- SBCI HC Yaroslavl region "Central City Hospital", Yaroslavl, Russia
- King Abdulaziz Hospital-Al Ahsa-National Guard, Al Ahsa, Saudi Arabia
- King Khaled University Hospital,King Saud Univ. Med. City, Riyadh, Saudi Arabia
- King Faisal Specialist Hospital & Research Centre, Riyadh, Riyadh, Saudi Arabia
- King Fahad Medical City, Riyadh, Saudi Arabia
- Phoenix Pharma, Port Elizabeth, Eastern Cape, South Africa
- Dr Wilhase's rooms, Boksburg, Gauteng, South Africa
- Chris Hani Baragwanath Hospital, Johannesburg, Gauteng, South Africa
- Botho ke Bontle Health Services, Pretoria, Gauteng, South Africa
- Dr J Reddy, Durban, KwaZulu-Natal, South Africa
- Lenmed Shifa Private Hospital, Durban, KwaZulu-Natal, South Africa
- Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
- Hospital Clinico San Carlos, Madrid, Spain
- Clínica Nuevas Tecnologías en Diabetes y Endocrinología, Seville, Spain
- Forskningsmottagning Internmedicin (tidigare KFE), Malmö, Sweden
- Medicinkliniken Överviktsenheten USÖ, Örebro, Sweden
- S:t Göran Sjukhus, Stockholm, Sweden
- Department of Metabolism and Endocrinology, Stockholm, Sweden

## Recent Field Changes (last 30 days)

- `locations.westside center for clinical research|jacksonville|florida|united states` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.baptist health system|montgomery|alabama|united states` — added _(2026-05-12)_
- `locations.ortho arizona|phoenix|arizona|united states` — added _(2026-05-12)_
- `locations.anaheim clinical trials, llc|anaheim|california|united states` — added _(2026-05-12)_
- `locations.stuart l. silverman md - a medical corporation|beverly hills|california|united states` — added _(2026-05-12)_
- `locations.valley research|fresno|california|united states` — added _(2026-05-12)_
- `locations.providence medical foundation|fullerton|california|united states` — added _(2026-05-12)_
- `locations.desert oasis hlthcr med group|palm springs|california|united states` — added _(2026-05-12)_
- `locations.encompass clinical research_spring valley|spring valley|california|united states` — added _(2026-05-12)_
- `locations.diablo clinical research, inc.|walnut creek|california|united states` — added _(2026-05-12)_
- `locations.clinical research of hollywood_hollywood|hollywood|florida|united states` — added _(2026-05-12)_
- `locations.jacksonville ctr for clin res|jacksonville|florida|united states` — added _(2026-05-12)_
- `locations.well pharma medical research corp|miami|florida|united states` — added _(2026-05-12)_
- `locations.renstar medical research|ocala|florida|united states` — added _(2026-05-12)_
- `locations.clinical trial res assoc,inc|plantation|florida|united states` — added _(2026-05-12)_
- `locations.east west medical research institute_honolulu|honolulu|hawaii|united states` — added _(2026-05-12)_
- `locations.clinical invest special_gurnee|gurnee|illinois|united states` — added _(2026-05-12)_
- `locations.evanston premier hlthcr res|skokie|illinois|united states` — added _(2026-05-12)_
- `locations.clinical invest special_gurnee|wauconda|illinois|united states` — added _(2026-05-12)_
- `locations.medisphere medical rc|evansville|indiana|united states` — added _(2026-05-12)_
- `locations.velocity clin. res valparaiso|valparaiso|indiana|united states` — added _(2026-05-12)_
- `locations.ku medwest|shawnee mission|kansas|united states` — added _(2026-05-12)_
- `locations.l-marc research center|louisville|kentucky|united states` — added _(2026-05-12)_
- `locations.maryland veterans administration health care system|baltimore|maryland|united states` — added _(2026-05-12)_
- `locations.centennial medical group|elkridge|maryland|united states` — added _(2026-05-12)_
- `locations.brigham & women's hospital|boston|massachusetts|united states` — added _(2026-05-12)_
- `locations.arcturus healthcare, plc.|troy|michigan|united states` — added _(2026-05-12)_
- `locations.studymetrix research llc|city of saint peters|missouri|united states` — added _(2026-05-12)_
- `locations.the center for pharmaceutical research pc|kansas city|missouri|united states` — added _(2026-05-12)_
- `locations.sundance clinical research llc|st louis|missouri|united states` — added _(2026-05-12)_
- `locations.nyu langone medical cent-joan h tisch cnt for women's health|new york|new york|united states` — added _(2026-05-12)_
- `locations.hospital for special surgery|new york|new york|united states` — added _(2026-05-12)_
- `locations.rochester clinical research, inc.|rochester|new york|united states` — added _(2026-05-12)_
- `locations.davita clinical research - new york|the bronx|new york|united states` — added _(2026-05-12)_
- `locations.southgate medical group, llp|west seneca|new york|united states` — added _(2026-05-12)_
- `locations.great lakes medical research|westfield|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05064735.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05064735*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*